Raytheon Technologies Corp vs GeneDx Holdings Corp — how do they compare? Raytheon Technologies Corp trades at $220.83 (market cap $301.71B), while GeneDx Holdings Corp trades at $82.1 (market cap $2.44B). The key difference: Raytheon Technologies Corp is far larger — about 123.7× GeneDx Holdings Corp's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| RTX | WGS | |
|---|---|---|
Market Cap | $301.71B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $224.12 | $167.51 |
52-Week Low | $151.75 | $34.51 |
Enterprise Value | $332.26B | $2.48B |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
RTX trades at $224.12, up 0.49% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $223. Fundamentally, revenue grew to $88.6B in 2025 with net income of $6.73B, and recent contract wins like the $515M SPY-6 radar award bolster growth prospects. Earnings have consistently beaten estimates, with Q2 2026 EPS of $1.89 exceeding expectations.
The outlook is positive given robust defense spending and operational execution, but valuation multiples like a P/E of 39.41 pose risks if growth slows. Analyst consensus is bullish with a $233.14 price target, though overbought RSI levels suggest near-term consolidation may occur. Key risks include execution delays and macroeconomic pressures on defense budgets.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →